This 2021 randomized, double-blind, placebo-controlled pilot study by Grilo et al. evaluated the efficacy and safety of a 16-week treatment with naltrexone/bupropion (NB) in adults with binge-eating disorder (BED) and obesity. Thirty-two participants (mean age 46.6 years; 84% female; mean BMI 37.2 kg/m²) were randomized to receive either NB or
